Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
about
Emerging molecularly targeted therapies in castration refractory prostate cancerStructures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001Galeterone for the treatment of advanced prostate cancer: the evidence to dateCYP17 inhibitors in prostate cancer: latest evidence and clinical potentialQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesRecent progress in pharmaceutical therapies for castration-resistant prostate cancerAndrogen biosynthesis in castration-resistant prostate cancerCYP17 inhibitors for prostate cancer therapyHE3235 inhibits growth of castration-resistant prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerAdvances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.New frontiers in androgen biosynthesis and metabolism.Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsBeyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Novel drugs targeting the androgen receptor pathway in prostate cancer.CYP17A1 inhibitors in castration-resistant prostate cancerAbiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerNew hormonal therapies for castration-resistant prostate cancer.Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerChanging paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerComparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular DynamicsGaleterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.Androgen pathway resistance in prostate cancer and therapeutic implicationsAndrogen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceNew players for advanced prostate cancer and the rationalisation of insulin-sensitising medicationNovel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspectiveSerially heterotransplanted human prostate tumours as an experimental modelStarving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetMolecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
P2860
Q21284745-08179FB4-668F-4EF2-959D-9CA6186BD825Q24302773-9D849AF2-CD6C-4277-A145-EC1B60C49651Q26739887-EC91122F-1B49-47E7-9E28-5664C5AC6FDAQ26740070-B730AF4A-5BC7-4F2C-A8D7-0AF5E8B1DED5Q27011642-578571CE-9DE4-4EA3-AC7F-651840CFEA5EQ27022567-963BF914-ACDE-4C41-937E-922784547F2FQ27026044-10A2698C-EBB6-4775-B196-520BCDC080B9Q28298818-969B451F-ACC2-4B8D-A8E8-C5C3803BD9BBQ30491204-540B310E-ECB7-4832-AB85-C8B8F65F7A3BQ33621403-E1C8E9BF-554E-449B-BBED-50231E0E56CDQ33754817-766DC357-D6B0-4CE9-9846-A7EEC5A9D10FQ33823702-BBEBC84A-781C-45C6-AB09-52330123437AQ33990433-54EE0B90-7BD0-4985-9F15-9C8F45D38E11Q34100727-F6A6736D-F99C-491E-9EE8-263DF280D9F9Q34250227-8224E36A-02EE-4932-BFC2-4EB901307B17Q34291736-1009BCB1-E4D9-413F-A50B-BE94A76DB9FDQ34310143-FF99B4C6-79C6-4C6D-A51F-F484AD6AE48EQ34324736-7E834288-C5E4-452F-85E6-172137504561Q34375823-8C9C515F-B715-44E3-8B42-0EDE4133D746Q34387852-8EDA8AEC-2810-4388-9553-1AA192561958Q34395777-D7D94BB6-1797-4872-A794-7DD4F93E91EBQ34456638-FF141DB7-B967-4B85-B0C9-649BEC8ACBBCQ34619574-4D820DF4-8D64-472E-A5AC-65C7E29224D8Q34956110-A17763F7-0730-4E32-AB21-97323C814620Q35196715-964883E6-0569-48BD-84BE-609F8C77CD63Q35209369-C8D0B114-5D85-414E-979D-122A7A1D2F2CQ35210730-600BFF93-B1AD-4CD0-97F0-D687B8E245CAQ35213324-DA0C3863-6293-4C1F-8C24-66FE83721D18Q35786826-F94B650E-5CDD-4741-A514-BA05F032B012Q36297428-3F24A6FB-40F3-4E29-A44F-165161DA7914Q36413805-9AAB603F-8728-42BC-A9A9-FE9D301B6A0BQ36416370-7E51F2EC-21D9-40AB-9051-3CCFE07EE417Q36470627-F9E11ECE-C193-4FCA-A5EA-3FD6C75A805AQ36734036-C7223216-AD31-4A4E-93F2-D1C4E27187A6Q36997189-F2B25B62-D94D-4B46-89CF-7B51DD079F9FQ37044229-156443CE-021A-4A6F-8EA9-6C0EB0527545Q37310963-14409FA3-4802-4112-9667-3A125D6937C6Q37564765-E6D9A7EF-E4EE-4178-B083-2004E1AABECAQ37606741-AD8B2F8C-9121-4F56-9FF3-86AEBAFD02D4Q37620953-6D99090E-3CD3-42E2-B427-FD9697CE0A9C
P2860
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Androgen receptor inactivation ...... 5,16-diene in prostate cancer.
@en
Androgen receptor inactivation ...... 5,16-diene in prostate cancer.
@nl
type
label
Androgen receptor inactivation ...... 5,16-diene in prostate cancer.
@en
Androgen receptor inactivation ...... 5,16-diene in prostate cancer.
@nl
prefLabel
Androgen receptor inactivation ...... 5,16-diene in prostate cancer.
@en
Androgen receptor inactivation ...... 5,16-diene in prostate cancer.
@nl
P2093
P2860
P1476
Androgen receptor inactivation ...... -5,16-diene in prostate cancer
@en
P2093
Aakanksha Khandelwal
Aashvini Belosay
Adam Schayowitz
Angela M H Brodie
Hong-Bin Fang
Lalji K Gediya
Pankaj Chopra
Tadas Vasaitis
Zhiyong Guo
P2860
P304
P356
10.1158/1535-7163.MCT-08-0230
P577
2008-08-01T00:00:00Z